Tirbanibulin Attenuates Pulmonary Fibrosis by Modulating Src/STAT3 Signaling
Tirbanibulin (KX-01) is the first clinical Src inhibitor of the novel peptidomimetic class that targets the peptide substrate site of Src providing more specificity toward the Src kinase. This study assessed the impact of KX-01 on cobalt chloride (CoCl2)-treated L929 cells and bleomycin (BLM)-induce...
Main Authors: | Xin Wang, Rui Ren, Zehui Xu, Haidi Huang, Wanglin Jiang, Jinbo Ma |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-07-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.693906/full |
Similar Items
-
Topical tirbanibulin eradication of periungual squamous cell carcinoma
by: Angela Yen Moore, MD, et al.
Published: (2021-08-01) -
A balancing act between the 'Src-Stat3' and 'p53-caldesmon' pathways dictates the outcome of Src-induced invasive phenotypes
by: Mooney, Patrick
Published: (2010) -
Src family kinases and pulmonary fibrosis: A review
by: Hang Li, et al.
Published: (2020-07-01) -
STAT3/HIF-1α signaling activation mediates peritoneal fibrosis induced by high glucose
by: Xiaoxiao Yang, et al.
Published: (2021-06-01) -
Ginsenoside Rg3 inhibits pulmonary fibrosis by preventing HIF-1α nuclear localisation
by: Zhuo Fu, et al.
Published: (2021-02-01)